A Phase 2 interventional study of Lenvatinib and Ifosfamide in Osteosarcoma, sponsored by Eisai Inc.. Completed at 84 sites in 21 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-07-22.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 278 studies in Osteosarcoma with a site in United States — 55 open to participants now, 83 under way, 1 of them phase 3. Osteosarcoma · United States.
Among the 278 studies in Osteosarcoma with a site in United States, this one is the 49th largest by enrollment of the 229 interventional ones that give a count, is one of 10 that started in 2020, is one of 97 in phase 2, and was the 208th registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →55 of the 278 studies in Osteosarcoma with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 7–22
Emory University · Sites in United States
Ages up to 50
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
St. Jude Children's Research Hospital · Sites in United States
Baylor College of Medicine · Sites in United States
Ages 1–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 124 · Phase 2 131 · Phase 3 8
First in 1986; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 30 across the 229 interventional studies, 155 across the 32 observational. Of the 179 that completed or were terminated, 66 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 278 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 2 studies filed under Osteosarcoma — fewer than ten, so there is no comparison to draw.
28 of the studies in Osteosarcoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129226Case Comprehensive Cancer CenterMusculoskeletal Cancers Remote Monitoring and Care | 2026-11 |
| NCT02508038University of Wisconsin, MadisonAlpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | 2026-12 |
| NCT02013336South Plains Oncology ConsortiumPhase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | 2026-12 |
| NCT05400603Emory UniversityAllogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
Add all 28 to your calendar (.ics) → With an account.
Among the 278 studies in Osteosarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as:
BP \<95th percentile for sex, age, and height/length at screening (as per National Heart Lung and Blood Institute guidelines) and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1. Participants >18 years of age should have BP less than or equal to (\<=) 150/90 millimeters of Mercury at screening and no change in antihypertensive therapy within 1 week prior to Cycle 1 Day 1
Eligibility for optional lenvatinib crossover:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
Drug: Lenvatinib · Drug: Ifosfamide · Drug: Etoposide
Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
Drug: Ifosfamide · Drug: Etoposide · Drug: Lenvatinib
Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor. An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules.
Also known as: E7080
Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
Also known as: E7080
Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment
PFS as assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of PD or date of death (whichever occurred first), as determined using RECIST v1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.
Time frame: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first (up to 20.5 months)
Percentage of Participants With PFS at Month 4 (PFS-4m Rate) by IIR Assessment
PFS rate at 4 months as assessed by IIR was defined as the percentage of participants who were alive and without PD at 4 months from the randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. The PFS-4m was estimated using the Kaplan-Meier method.
Time frame: Month 4
Percentage of Participants With PFS at 1 Year or Month 12 (PFS-1y Rate) by IIR Assessment
PFS-1y rate as assessed by IIR was defined as the percentage of participants who were alive and without PD at 1 year from randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS-1y rate was estimated using Kaplan-Meier method.
Time frame: Month 12 or 1 Year
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. The median OS was from Kaplan-Meier product-limit estimates and 2-sided 95% CIs from a generalized Brookmeyer and Crowley method.
Time frame: From the date of randomization to the date of death from any cause (up to 37.1 months)
Percentage of Participants With Overall Survival at 1 Year or Month 12 (OS-1y)
OS-1y was defined as the time from the date of randomization to the date of death from any cause assessed up to 1 year. OS was calculated using the Kaplan-Meier method.
Time frame: Month 12 or 1 Year
Objective Response Rate at Month 4 (ORR-4m) by IIR Assessment
ORR-4m was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST v1.1 within the first 4 months. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% confidence interval (CI) of ORR was calculated using the method of Clopper and Pearson.
Time frame: Month 4
ORR by IIR Assessment
ORR by IIR was defined as the percentage of participants with best overall response of CR or PR determined using RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% CI of ORR was calculated using the method of Clopper and Pearson.
Time frame: From the date of randomization to the date of the first documentation of CR or PR (up to 20.5 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
TEAE was defined as an adverse event (AE) that emerged during time from first dose to 30 days following last dose of drug, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to pretreatment state, when AE was continuous. Serious adverse events (SAE) was defined as untoward medical occurrence that at any dose resulted in death; was life threatening; resulted in persistent or significant disability; was congenital anomaly or medically important due to other reasons than above mentioned criteria.
Time frame: From first dose up to 30 days after the last dose of study drug (up to 40.8 months)
Treatment Arm A: Plasma Concentration of Lenvatinib
Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: Pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: Pre-dose (each Cycle length = 21 days)
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Scale: Generic Core Scale Score at Month 4
Health-Related Quality of Life (HRQoL): PedsQL 4.0 Generic Core Scale is a multidimensional scale. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (5 items - children greater than or equal to \[\>=\] 5 years, adults; 3 items - toddlers \[aged 2-4 years\]). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Generic Core Scale total score: sum of all the items divided by the number of items answered across all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL.
Time frame: Baseline and Month 4
Change From Baseline in PedsQL Scale: Cancer Module Scale Score at Month 4
HRQoL: PedsQL 3.0 Cancer Module Scale measured pediatric cancer-specific HRQoL. It included assessment of 8 dimensions: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), cognitive problems (3 items - toddlers \[aged 2-4\], 4 items - young children \[aged 5-7\]; 5 items for children aged \>=8 years, adults), perceived physical appearance (3 items), communication (3 items). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Cancer Module total score: sum of all items divided by the number of items answered on all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL.
Time frame: Baseline and Month 4
Number of Participants Categorized Based on Overall Palatability and Acceptability Questionnaire Responses for Suspension of Lenvatinib
The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses.
Time frame: Cycle 1 Day 1 (Cycle length = 21 days)
Participants took part in the study at 84 investigative sites in Austria, Australia, Belgium, Hong Kong, Korea, New Zealand, Singapore, Taiwan, Czech Republic, Finland, France, Israel, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Canada, and the United States.
| Milestone | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Started | 40 | 41 |
| Treated (safety analysis set) | 39 | 39 |
| Optional lenvatinib treatment (arm b only) | 0 | 16 |
| Completed | 0 | 0 |
| Not completed | 40 | 41 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Survival follow-up discontinued by sponsor | 8 | 10 |
| Withdrew: Participants transitioned to patient access program (pap) | 1 | 0 |
| Withdrew: Participants transitioned to managed access program (map) | 2 | 0 |
| Withdrew: Death | 25 | 25 |
PFS as assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of PD or date of death (whichever occurred first), as determined using RECIST v1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.
| months | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment | 6.5 (5.7 to 8.2) | 5.5 (2.9 to 6.5) |
PFS rate at 4 months as assessed by IIR was defined as the percentage of participants who were alive and without PD at 4 months from the randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. The PFS-4m was estimated using the Kaplan-Meier method.
| percentage of participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Percentage of Participants With PFS at Month 4 (PFS-4m Rate) by IIR Assessment | 76.3 (59.3 to 86.9) | 66.0 (47.7 to 79.2) |
PFS-1y rate as assessed by IIR was defined as the percentage of participants who were alive and without PD at 1 year from randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS-1y rate was estimated using Kaplan-Meier method.
| percentage of participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Percentage of Participants With PFS at 1 Year or Month 12 (PFS-1y Rate) by IIR Assessment | NA (NA to NA) | 14.9 (1.1 to 44.5) |
OS was defined as the time from the date of randomization to the date of death from any cause. The median OS was from Kaplan-Meier product-limit estimates and 2-sided 95% CIs from a generalized Brookmeyer and Crowley method.
| months | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Overall Survival (OS) | 12.4 (10.4 to 19.8) | 17.2 (11.1 to 22.3) |
OS-1y was defined as the time from the date of randomization to the date of death from any cause assessed up to 1 year. OS was calculated using the Kaplan-Meier method.
| percentage of participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Percentage of Participants With Overall Survival at 1 Year or Month 12 (OS-1y) | 49.2 (28.5 to 67.0) | 72.1 (54.2 to 83.9) |
ORR-4m was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST v1.1 within the first 4 months. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% confidence interval (CI) of ORR was calculated using the method of Clopper and Pearson.
| percentage of participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Objective Response Rate at Month 4 (ORR-4m) by IIR Assessment | 15.0 (5.7 to 29.8) | 7.3 (1.5 to 19.9) |
ORR by IIR was defined as the percentage of participants with best overall response of CR or PR determined using RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% CI of ORR was calculated using the method of Clopper and Pearson.
| percentage of participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| ORR by IIR Assessment | 15.0 (5.7 to 29.8) | 9.8 (2.7 to 23.1) |
TEAE was defined as an adverse event (AE) that emerged during time from first dose to 30 days following last dose of drug, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to pretreatment state, when AE was continuous. Serious adverse events (SAE) was defined as untoward medical occurrence that at any dose resulted in death; was life threatening; resulted in persistent or significant disability; was congenital anomaly or medically important due to other reasons than above mentioned criteria.
| Participants | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Participants with TEAEs | 38 | 39 |
| Participants with TESAEs | 30 | 20 |
Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.
| nanograms per milliliter (ng/mL) | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide |
|---|---|
| Cycle 1, Day 1: 0.5-4 hours post-dose | 147.9 ± 194.61 |
| Cycle 1, Day 1: 6-10 hours post-dose | 217.8 ± 99.54 |
| Cycle 1, Day 15: Pre-dose | 70.7 ± 43.48 |
| Cycle 1, Day 15: 0.5-4 hours post-dose | 222.3 ± 203.07 |
| Cycle 1, Day 15: 6-10 hours post-dose | 310.9 ± 106.79 |
| Cycle 2, Day 1: Pre-dose | 70.2 ± 67.95 |
Health-Related Quality of Life (HRQoL): PedsQL 4.0 Generic Core Scale is a multidimensional scale. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (5 items - children greater than or equal to \[\>=\] 5 years, adults; 3 items - toddlers \[aged 2-4 years\]). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Generic Core Scale total score: sum of all the items divided by the number of items answered across all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL.
| score on a scale | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Scale: Generic Core Scale Score at Month 4 | 2.61 ± 17.568 | 2.65 ± 4.128 |
HRQoL: PedsQL 3.0 Cancer Module Scale measured pediatric cancer-specific HRQoL. It included assessment of 8 dimensions: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), cognitive problems (3 items - toddlers \[aged 2-4\], 4 items - young children \[aged 5-7\]; 5 items for children aged \>=8 years, adults), perceived physical appearance (3 items), communication (3 items). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Cancer Module total score: sum of all items divided by the number of items answered on all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL.
| score on a scale | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide |
|---|---|---|
| Change From Baseline in PedsQL Scale: Cancer Module Scale Score at Month 4 | 2.66 ± 9.989 | 2.08 ± 6.736 |
The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses.
| Participants | All Participants: Lenvatinib 14 mg/m^2 |
|---|---|
| Super Bad | 0 |
| Really Bad | 0 |
| Bad | 0 |
| May be Good or May be Bad | 2 |
| Good | 2 |
| Really Good | 0 |
| Super Good | 1 |
Collected over From first dose up to 30 days after the last dose of study drug (up to 40.8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 25/40 (62.5%) | 30/39 (76.9%) | 38/39 (97.4%) |
| Treatment Arm B: Ifosfamide + Etoposide | 25/41 (61%) | 20/39 (51.3%) | 39/39 (100%) |
| Treatment Arm B: Ifosfamide+Etoposide to Lenvatinib (Optional) | 12/16 (75%) | 10/16 (62.5%) | 16/16 (100%) |
| Event | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide+Etoposide to Lenvatinib (Optional) |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 15/39 | 7/39 | 0/16 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 7/39 | 1/39 | 4/16 |
| PyrexiaGeneral disorders | 6/39 | 2/39 | 1/16 |
| Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/39 | 1/39 | 0/16 |
| Platelet count decreasedInvestigations | 3/39 | 0/39 | 0/16 |
| Toxic encephalopathyNervous system disorders | 3/39 | 0/39 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 1/39 | 0/39 | 1/16 |
| VomitingGastrointestinal disorders | 0/39 | 1/39 | 1/16 |
| PneumoniaInfections and infestations | 2/39 | 0/39 | 1/16 |
| HypertensionVascular disorders | 1/39 | 0/39 | 1/16 |
| Event | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide+Etoposide to Lenvatinib (Optional) |
|---|---|---|---|
| HypothyroidismEndocrine disorders | 35/39 | 0/39 | 8/16 |
| AnaemiaBlood and lymphatic system disorders | 28/39 | 27/39 | 2/16 |
| NauseaGastrointestinal disorders | 23/39 | 16/39 | 5/16 |
| Platelet count decreasedInvestigations | 23/39 | 17/39 | 3/16 |
| ProteinuriaRenal and urinary disorders | 21/39 | 5/39 | 6/16 |
| VomitingGastrointestinal disorders | 19/39 | 11/39 | 5/16 |
| HypertensionVascular disorders | 16/39 | 0/39 | 6/16 |
| Neutrophil count decreasedInvestigations | 15/39 | 13/39 | 1/16 |
| Back painMusculoskeletal and connective tissue disorders | 15/39 | 6/39 | 4/16 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/39 | 5/39 | 6/16 |
Full Analysis Set (FAS) included all randomized participants regardless of the treatment actually received.
| Age, Continuous(years) | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Total |
|---|---|---|---|
| Mean | 15.6 ± 3.76 | 14.3 ± 4.16 | 14.9 ± 3.99 |
| Sex: Female, Male(Participants) | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Total |
|---|---|---|---|
| Female | 15 | 20 | 35 |
| Male | 25 | 21 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 38 | 33 | 71 |
| Unknown or Not Reported | 0 | 5 | 5 |
| Race/Ethnicity, Customized(Participants) | Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | Treatment Arm B: Ifosfamide + Etoposide | Total |
|---|---|---|---|
| White | 24 | 26 | 50 |
| Black or African American | 1 | 1 | 2 |
| Asian | 13 | 7 | 20 |
| American Indian or Alaskan Native | 0 | 1 | 1 |
| Other | 2 | 4 | 6 |
| Missing | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Ran from Mar 2020 to primary completion in Jun 2022, 26 months.
Results were first posted in Aug 2023, 1 year 1 month after primary completion.
Of 76 phase 2 interventional studies under Osteosarcoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 94. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib